TrialDiabetes care2022

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.

Katherine R Tuttle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.